FY results highlight Summit’s advancing pipeline as a pure-play developer of new-mechanism antibiotics, Ridinilazole (targeting C. difficile infection, an area of unmet need due to high recurrence rates) recently entered Phase III trials, and we continue to expect SMT-571 (targeting N. gonorrhoeae infection, already on its last treatment option as a result of high and rising antibiotics resistance) to enter Phase I trials by year-end. In addition, encouraging development progress is being made on a number of earlier-stage programmes targeting hard-to-treat, priority pathogens (including gram negatives, which pose a particular healthcare threat). We reiterate our positive stance.
